Calidi Biotherapeutics (CLDI) Income from Non-Controlling Interests (2024 - 2025)
Calidi Biotherapeutics' quarterly Income from Non-Controlling Interests came in at -$3000.0 in Q4 2025, up 94.12% year-on-year from -$1545.5 in Q4 2024, and up 90.62% quarter-over-quarter from -$32000.0 in Q3 2025.
Calidi Biotherapeutics has reported Income from Non-Controlling Interests for 2 years, with the latest figure at -$3000.0 in Q4 2025.
- For the quarter ending Q4 2025, Income from Non-Controlling Interests rose 94.12% year-over-year to -$3000.0; the trailing twelve-month figure through Dec 2025 stood at -$157000.0 (changed N/A YoY), and the FY2025 full-year result was -$157000.0, down 137.88% from the prior year.
- Income from Non-Controlling Interests for Q4 2025 stood at -$3000.0, up from -$32000.0 in the prior quarter.
- The five-year high for Income from Non-Controlling Interests was -$3000.0 in Q4 2025, with the low at -$76000.0 in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | -13.75 Mn |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | - |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | - |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | - |
| 10 | Calidi Biotherapeutics | - | - | - | -3,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3,000.00 |
| Sep 30, 2025 | -32,000.00 |
| Jun 30, 2025 | -46,000.00 |
| Mar 31, 2025 | -76,000.00 |
| Dec 31, 2024 | -51,000.00 |
| Sep 30, 2024 | -15,000.00 |